Novel Treatment Options in Head and Neck Cancer

被引：8
|
作者：
Schuler, Patrick J. [1 ]
Laban, Simon [1 ]
Doescher, Johannes [1 ]
Bullinger, Lars [2 ]
Hoffmann, Thomas K. [1 ]
机构：
[1] Ulm Univ, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Frauensteige 12, D-89075 Ulm, Germany
[2] Ulm Univ, Med Ctr, Dept Internal Med 3, Ulm, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 06期
关键词：
HNSCC; Immunotherapy; PD-1; Immune escape; Vaccination; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; RECURRENT; TRIAL; IMMUNOTHERAPY; MULTICENTER; COMBINATION; VACCINATION; MECHANISM; NIVOLUMAB;
D O I：
10.1159/000477254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of head and neck squamous cell carcinoma (HNSCC) has been a medical challenge with limited improvement in overall survival over the past few decades. However, recently, very interesting innovations in the field of immunotherapy have been shown to be beneficial for patients with advanced HNSCC. In this article, the latest medical developments are reviewed with special focus on the clinical achievements and current clinical studies in the field of immunotherapy. The landscape of clinical studies has changed considerably from antibody-based growth factor inhibition towards immune checkpoint modulation, and new indications in the adjuvant and neoadjuvant setting are being tested in large patient cohorts. Even the combination of 2 or more immune modulatory approaches and the correct synchronization with standard cancer therapy is promising and warrants suitable clinical trials. (C) 2017 S. Karger GmbH, Freiburg
引用
收藏
页码：342 / 346
页数：5
相关论文
共 50 条
  • [21] Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions
    Uta, Rothschild
    Laurent, Muller
    Axel, Lechner
    Hans, Schloessr A.
    Dirk, Beutner
    Heinz, Laubli
    Alfred, Zippelius
    Sacha, Rothschild, I
    SWISS MEDICAL WEEKLY, 2018, 148
  • [22] Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
    Xu, Chang
    Nikolova, Olga
    Basom, Ryan S.
    Mitchell, Ryan M.
    Shaw, Reid
    Moser, Russell D.
    Park, Heuijoon
    Gurley, Kay E.
    Kao, Michael C.
    Green, Carlos L.
    Schaub, Franz X.
    Diaz, Robert L.
    Swans, Hallie A.
    Jang, In S.
    Guinney, Justin
    Gadi, Vijayakrishna K.
    Margolin, Adam A.
    Grandori, Carla
    Kemp, Christopher J.
    Mendez, Eduardo
    CLINICAL CANCER RESEARCH, 2018, 24 (12) : 2828 - 2843
  • [23] Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer
    Jones, Trace M.
    Carew, Jennifer S.
    Bauman, Julie E.
    Nawrocki, Steffan T.
    CANCERS, 2021, 13 (13)
  • [24] Targeting the kynurenine pathway as a novel metabolic treatment for head and neck cancer
    Subramanian, Chitra
    Rajendiran, Thekkelnaycke M.
    Soni, Tanu
    Cohen, Mark S.
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Novel therapeutics for head and neck cancer
    Kim, ES
    Kies, M
    Herbst, RS
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (03) : 334 - 342
  • [26] Head and neck cancers: Incidence, Epidemiological Risk, and Treatment Options
    Tariq, Ayesha
    Mehmood, Yasir
    Jamshaid, Muhammad
    Yousaf, Hamad
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2015, 4 (03): : 21 - 34
  • [27] Head and neck cancer: treatment of nasopharyngeal cancer
    Chan, ATC
    ANNALS OF ONCOLOGY, 2005, 16 : 265 - 268
  • [28] Particle therapy in head and neck cancer—expanding therapeutic options
    Petra Georg
    memo - Magazine of European Medical Oncology, 2020, 13 : 389 - 394
  • [29] Radioimmunotherapy for the treatment of head and neck cancer
    Karam, Sara D.
    Raben, David
    LANCET ONCOLOGY, 2019, 20 (08): : E404 - E416
  • [30] TREATMENT OF CANCER OF HEAD + NECK CHEMOTHERAPY
    BEAHRS, OH
    CALDAROLA, VT
    HARRISON, EG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1964, 189 (10): : 765 - &
12345